Collateral effects on non-target tissue are worse with pulsed-field ablation than with radiofrequency ablation, according to a study published April 24 in JACC: Clinical Electrophysiology.
The multicenter study, led by researchers from the Kansas City (Kan.) Heart Rhythm Institute, analyzed data from 871 patients who underwent pulsed-field ablation or radiofrequency ablation beginning March 2024 and onward.
Here are four notes on the study:
- Of the 773 patients who underwent pulsed-field ablation, 70.9% were with a pentaspline system, 14.1% with a circular multielectrode, 12.4% with a spherical and 2.3% with a variable loop catheter.
- Post-procedural changes associated with pulsed-field ablation included higher levels of troponin, lactate dehydrogenase and haptoglobin biomarkers, compared to the levels associated with radiofrequency ablation.
These changes were dose-dependent and varied across the pulsed-field ablation systems used. - There was also significant change in left atrial ejection fraction associated with pulsed-field ablation compared to radiofrequency ablation, at -5.0% and -20.0%, respectively.
- “As [pulsed-field ablation] becomes mainstream, future studies appraising these effects and understanding the short term and long-term implications are needed,” the study authors wrote.
Read the full study here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
